/LNAI
LNAI Stock - Lunai Bioworks Inc.
Healthcare|BiotechnologyNASDAQ
$1.05+1.94%
+$0.02 (+1.94%) • Dec 19
57
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.8
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $1.16
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for LNAI
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.04 – $1.06
TARGET (TP)$1.21
STOP LOSS$0.97
RISK/REWARD1:2.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.36
52W High$16.49
52W Low$0.81
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-129,094 | N/A | N/A | N/A | $-391,416 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-188,966,000 | $-81,639,296 | $-38,556,891 | $-116,079,191 | $-23,401,787 |
| Net Income | $-178,007,489 | $-88,425,828 | $-39,684,056 | $-113,433,392 | $-26,723,607 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-10.78 | $-9.10 | $-7.10 | $-21.60 | $-5.67 |
Company Overview
A company rebranding from Renovaro, focusing on AI-powered therapeutics and biodefense, with “Neurotoxicity Intelligence Technology” in development.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
LNAIBeat Rate
0%
Last 0 quarters
Avg Surprise
+0%
EPS vs Estimate
Beats / Misses
0/0
Last 12 quarters
Latest EPS
$0.13
Q4 2025
EPS Surprise History
Q4 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Feb 17, 2026 | — | — | — | — |
Q4 2025 | Nov 14, 2025 | — | $0.13 | — | — |
Latest News
Lunai Bioworks Identifies Three Parkinson's Disease Subtypes And Drug Targets To Accelerate Therapeutic Development In $13B Market
📈 PositiveBenzinga•Dec 9, 2025, 12:50 PM
Lunai Bioworks Secures First Letter Of Intent For Its Immune Cell Therapy
📈 PositiveBenzinga•Nov 25, 2025, 12:46 PM
Lunai Bioworks shares are trading higher after the company announced the publication of Second-Generation Allogeneic Dendritic Cell Therapy Platform in the journal "Vaccines".
📈 PositiveBenzinga•Nov 5, 2025, 03:05 PM
Lunai Bioworks Publishes Second-Gen Allogeneic Dendritic Cell Therapy In Vaccines Journal, Demonstrates Complete Pancreatic Tumor Regression In Humanized Mouse Models
📈 PositiveBenzinga•Nov 5, 2025, 02:28 PM
Lunai Bioworks Announces Early Results From AI-Based Platform Designed To Identify Compounds That Interact With Acetylcholinesterase, Same Molecular Target Affected By Nerve Agents
📈 PositiveBenzinga•Oct 30, 2025, 01:33 PM
Lunai Bioworks Says Nature Communications Study Identifies Prognostic Biomarkers For Duchenne Muscular Dystrophy Using SomaScan; Lunai Bioworks' BioSymetrics Leads Multi-Institutional Team With Leiden University And University Of Florida
📈 PositiveBenzinga•Oct 16, 2025, 01:51 PM
Lunai Bioworks Regains Nasdaq Compliance
📈 PositiveBenzinga•Oct 16, 2025, 01:16 PM
Lunai Bioworks Reports 35% Improvement In Alzheimer's Diagnostic Accuracy Via Augusta AI; Launches Preclinical Program For Early Intervention
📈 PositiveBenzinga•Oct 6, 2025, 01:18 PM
Lunai Bioworks Adopts New Corporate Identity, To Trade Under New Ticker Symbol "LNAI" On Nasdaq Capital Market, Effective Sept 30
➖ NeutralBenzinga•Sep 30, 2025, 01:43 PM•Also:
Frequently Asked Questions about LNAI
What is LNAI's current stock price?
Lunai Bioworks Inc. (LNAI) is currently trading at $1.05 per share. The stock has moved +1.94% today.
What is the analyst price target for LNAI?
No analyst price targets are currently available for this stock.
What sector is Lunai Bioworks Inc. in?
Lunai Bioworks Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is LNAI's market cap?
Lunai Bioworks Inc. has a market capitalization of $0.02 billion, making it a small-cap company.
Does LNAI pay dividends?
No, Lunai Bioworks Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorADAP
Adaptimmune Therapeutics plc
$0.05
Mkt Cap: $0.0B
ANL
Adlai Nortye Ltd.
$1.52
Mkt Cap: $0.0B
APLM
Apollomics, Inc.
$16.73
Mkt Cap: $0.0B
BLRX
BioLineRx Ltd.
$3.04
Mkt Cap: $0.0B
ERNA
Ernexa Therapeutics Inc.
$1.31
Mkt Cap: $0.0B
GOVX
GeoVax Labs, Inc.
$0.16
Mkt Cap: $0.0B
ICU
SeaStar Medical Holding Corporation
$0.24
Mkt Cap: $0.0B
LPCN
Lipocine Inc.
$4.25
Mkt Cap: $0.0B
MBRX
Moleculin Biotech, Inc.
$3.90
Mkt Cap: $0.0B
THAR
Tharimmune, Inc.
$2.32
Mkt Cap: $0.1B
Explore stocks similar to LNAI for comparison